Related Experiment Videos
D lucus antigen defined lymphoblastoid cell panel allows detection of hitherto undetected adverse presensitization
Proceedings of the Clinical Dialysis and Transplant Forum
|November 18, 1978
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Butyrate-induced differentiation in leukemic myeloid cells - in-vitro and in-vivo studies.
International journal of oncology·2011
Tyrphostins reduce chemotherapy-induced intestinal injury in mice: assessment by a biochemical assay.
British journal of cancer·2005
Kidney transplantation in patients with type 1 diabetes mellitus: long-term prognosis for patients and grafts.
The Korean journal of internal medicine·2001
Urinary stones following renal transplantation.
The Korean journal of internal medicine·2001
Exercise-induced bronchospasm prevalence in collegiate cross-country runners.
Medicine and science in sports and exercise·2001
Relationship of hypolipidemia to cytokine concentrations and outcomes in critically ill surgical patients.
Critical care medicine·2001
Hemodialysis without heparin infusion using Cordis Dow 3500 hollow fiber.
Proceedings of the Clinical Dialysis and Transplant Forum·1980
Acid-base balance in continuous ambulatory peritoneal dialysis.
Proceedings of the Clinical Dialysis and Transplant Forum·1980
Improved results in high risk cadaveric kidney transplantation.
Proceedings of the Clinical Dialysis and Transplant Forum·1980
High prevalence of autoantibodies neutralizing type I IFNs in Japanese patients with hepatitis C.
Journal of human immunity·2026
Immunosenescence and immune-organ axis dysfunction: Potential of algal bioactives and nutritional interventions for healthy ageing.
International reviews of immunology·2026
Brief Communication: LSD1 Inhibition Enhances Susceptibility of Primary AML Cells for NK Cell-Mediated Killing.
Journal of immunotherapy (Hagerstown, Md. : 1997)·2026
Somatic Hypermutations Enhance Neutralization Breadth of IGHV3-53/3-66 Public Antibodies Against SARS-CoV-2 Variants.
Immunity, inflammation and disease·2026